RHOH and neoplasm: tTF-NGR retained the procoagulatory activity of TF in a FX/FXa assay [69,70,71] and it revealed specific binding to the respective target molecules (CD13) on stimulated endothelial cells in vitro [70,71,72] and to tumor endothelium in vivo [65].